Preview

September 2019

In the next issue of Pharma Technology Focus, we explore the benefits of real world data, take a look at the life and achievements of renowned immunologist Dr. Teruko Ishizaka, and examine the rise of buyers clubs for cystic fibrosis patients seeking to bypass unsuccessful price negotiations in order to access treatments in the UK.


Also, we take a look at attitudes to pharmaceutical treatment for mental health conditions and explore the knock-on effects of overusing antibiotics in animals.


Plus, we find out how researchers are working to fill the vast gaps in knowledge that exist around the use of medication during pregnancy and breast feeding, speak to SIX head of securities and exchanges Thomas Zeeb to discuss the skills, regulations and protections that make Switzerland a good home for pharma firms, and investigate the cancer-killing power of halichondrin.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Abi Millar, Chris Lo
Magazine Designer | Marzia Del Gaone

Graphic Designers | Kate Cuntapay, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2019 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Taming the pharma beastGo to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: TSS Company InsightGo to article: NewsGo to article: Daiichi JitsugyoGo to article: ICCI Company InsightGo to article: ICCIGo to article: The pharma industry briefingGo to article: Novo NordiskGo to article: Swiss WorldCargoGo to article: Understanding drug-resistant TBGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: Through time: the breakthroughs that changed the course of HIV treatmentGo to article: Senn ChemicalsGo to article: Qatar AirwaysGo to article: Trouble at Teva: US price-fixing lawsuit adds to generic giant’s woesGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: The dangers of unlicensed stem cell clinicsGo to article: Komtur PharmaceuticalsGo to article: How do cancer cells communicate and can it help us catch them?Go to article: Verona’s ensifentrine: a potentially revolutionary treatment for COPDGo to article: Taming the pharma monster with Hedley ReesGo to article: Capsugel Company InsightGo to article: Altheria SolutionsGo to article: ‘Pay As You Go’ AI for drug discoveryGo to article: AtoZ-CRO GmbHGo to article: PharmaHempGo to article: Event: CPhl KoreaGo to article: EventsGo to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: Next issueGo to article: Hapa Company InsightGo to article: Pfanstiehl